By Josh Beckerman
Palisade Bio shares rose 40% to 73 cents after-hours.
The company withdrew its Dec. 29 S-1 filing for a stock offering on Friday, and said it will seek stockholder approval for a potential reverse split.
Palisade focuses on chronic gastrointestinal diseases. On Jan. 9, the company said a poster presentation on lead product candidate PALI-2108 was scheduled for late Friday at this week’s Crohn’s & Colitis Congress.
Write to Josh Beckerman at [email protected]
Read the full article here
